Grant of 13,000 RSUs to Spruce Biosciences (SPRB) Chief Medical Officer

Q: What insider equity award did Spruce Biosciences (SPRB) grant to its Chief Medical Officer?

Spruce Biosciences granted its CMO 13,000 Restricted Stock Units (RSUs) . The RSUs were awarded on July 27, 2026 and each unit represents one share of common stock, providing additional equity-based compensation tied to the company’s future performance.

Q: How many shares of Spruce Biosciences (SPRB) stock are covered by the new RSU grant?

The grant covers 13,000 RSUs , each convertible into one share of common stock. This means the award represents rights to receive up to 13,000 shares, subject to the vesting schedule and the executive’s continuous service with the company.

Q: What is the vesting schedule for the 13,000 RSUs reported by SPRB?

The 13,000 RSUs vest in four equal annual installments . 25% vest on June 15, 2027, and an additional 25% vest on June 15 of each year in 2028, 2029, and 2030, contingent on the executive’s continuous service.

Q: What conditions apply to the RSU award disclosed by Spruce Biosciences (SPRB)?

The RSUs vest only if the executive maintains Continuous Service under Spruce Biosciences’ 2020 Equity Incentive Plan. Vesting occurs on specified June 15 dates from 2027 through 2030, so leaving the company before those dates could affect the ultimate shares received.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Quartel Adrian W reported acquisition or exercise transactions in this Form 4 filing.

Spruce Biosciences’ Chief Medical Officer Adrian W. Quartel reported a grant of 13,000 Restricted Stock Units (RSUs) on July 27, 2026. Each RSU represents one share of common stock. The award vests 25% on June 15 of each year from 2027 through 2030, subject to his continuous service, resulting in direct holdings of 13,000 RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Quartel Adrian W

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units ^{F1, F2}	13,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 13,000 shares (Direct)

Footnotes (2)

F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2. 25% of the total number of restricted stock units ("RSUs") will vest on June 15, 2027. 25% of the total number of RSUs will vest on each of June 15, 2028, June 15, 2029 and June 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date.

Key Figures

RSUs granted: 13000.0000 Underlying common shares: 13000.0000 Transaction price per RSU: 0.0000 +2 more

5 metrics

RSUs granted 13000.0000 Restricted Stock Units awarded to the Chief Medical Officer on July 27, 2026

Underlying common shares 13000.0000 Each RSU represents a contingent right to receive one share of common stock

Transaction price per RSU 0.0000 Reported per-unit price for the grant of Restricted Stock Units

Post-grant RSU holdings 13000.0000 Total RSUs directly held by the executive following this award

First vesting date June 15, 2027 25% of the total RSUs vest on this date, subject to continuous service

Key Terms

Restricted Stock Units, Continuous Service, 2020 Equity Incentive Plan

3 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Continuous Service regulatory

"subject to the Reporting Person's Continuous Service as of each such vesting date"

2020 Equity Incentive Plan financial

"as defined in the Issuer's 2020 Equity Incentive Plan"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 04:11 PM Accepted by SEC EDGAR 07/29/2026 - 04:10 PM

FAQ

What insider equity award did Spruce Biosciences (SPRB) grant to its Chief Medical Officer?

Spruce Biosciences granted its CMO 13,000 Restricted Stock Units (RSUs). The RSUs were awarded on July 27, 2026 and each unit represents one share of common stock, providing additional equity-based compensation tied to the company’s future performance.

How many shares of Spruce Biosciences (SPRB) stock are covered by the new RSU grant?

The grant covers 13,000 RSUs, each convertible into one share of common stock. This means the award represents rights to receive up to 13,000 shares, subject to the vesting schedule and the executive’s continuous service with the company.

What is the vesting schedule for the 13,000 RSUs reported by SPRB?

The 13,000 RSUs vest in four equal annual installments. 25% vest on June 15, 2027, and an additional 25% vest on June 15 of each year in 2028, 2029, and 2030, contingent on the executive’s continuous service.

What conditions apply to the RSU award disclosed by Spruce Biosciences (SPRB)?

The RSUs vest only if the executive maintains Continuous Service under Spruce Biosciences’ 2020 Equity Incentive Plan. Vesting occurs on specified June 15 dates from 2027 through 2030, so leaving the company before those dates could affect the ultimate shares received.

How many RSUs does the Spruce Biosciences (SPRB) CMO hold after this transaction?

Following this award, the Chief Medical Officer directly holds 13,000 RSUs. These units will convert into common shares only as they vest over time according to the four-year schedule, aligning his compensation more closely with long-term shareholder outcomes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quartel Adrian W

(Last)

(First)

(Middle)

C/O SPRUCE BIOSCIENCES, INC.

611 GATEWAY BOULEVARD, SUITE 740

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0⁽¹⁾	07/27/2026		A		13,000		⁽²⁾	⁽²⁾	Common Stock	13,000	$0	13,000	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. 25% of the total number of restricted stock units ("RSUs") will vest on June 15, 2027. 25% of the total number of RSUs will vest on each of June 15, 2028, June 15, 2029 and June 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date.

	/s/ Samir Gharib, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR